Since both WT1 and p53 are tumour-associated antigens and WT1 is ranked first in pilot prioritisation out of 75 cancer antigens based on predefined criteria including therapeutic efficacy and immunogenicity,13 these proteins offer targets for therapy of lethal OvCa. This evidence concerns the gene WT1 and neoplasm.